Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 117Triple Negative Breast Neoplasms 27Neoplasm Metastasis 15Ovarian Neoplasms 5Brain Neoplasms 4Neoplasms 3Inflammatory Breast Neoplasms 3HER2-negative Breast Cancer 3Sarcoma 2Recurrence 2Prostatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Advanced Breast Cancer 2Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neurotoxicity Syndromes 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Metastatic HER2-positive Breast Cancer 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Lung Neoplasms 1Ketosis 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1HR+HER2- Breast Cancer 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2-negative Metastatic Breast Cancer 1

Interventions

eribulin 1Trastuzumab 1Paclitaxel 1Mental Status and Dementia Tests 1Magnetic Resonance Spectroscopy 1Ginkgo Extract 1Fluorodeoxyglucose F18 1Exercise Therapy 1Doxorubicin 1Docetaxel 1Cycloserine 1Cyclophosphamide 1Carnitine 1Carboplatin 1Aromatase Inhibitors 1Amifostine 1Acupuncture Therapy 12,2'-dithiodiethanesulfonic acid 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurotoxicity Syndromes × eribulin × Breast × Clear all
NCT02864030 2021-03-04

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

Oncologia Medica dell'Ospedale Fatebenefratelli

Phase 4 Completed
200 enrolled
Breast

Breast Neoplasms, Neurotoxicity Syndromes, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡